The study about the effects of cholesterol absorption inhibition on coronary artery plaque in patients treated with PCI
Not Applicable
Completed
- Conditions
- coronary artery diseases
- Registration Number
- JPRN-UMIN000026581
- Lead Sponsor
- Kurume University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) prior taking ezetimibe, 2) recent acute coronary syndrome (< 1 year), 3) renal insufficiency (serum creatinine > 2.0 mg / dL), 4) hepatic dysfunction (serum AST or ALT > 3-folds of standard value), 5) cancer, 6) autoimmune diseases, 7) impossibility in decision making 8) consideration as inadequate to participating in the study by attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method coronary artery plaque, 1 years after
- Secondary Outcome Measures
Name Time Method clinical events 3 years after lipid profile 1 years after